The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions.
暂无分享,去创建一个
[1] S. Rennard,et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[2] Takahiko Horiuchi,et al. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. , 2008, Arthritis and rheumatism.
[3] L. Peyrin-Biroulet,et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[4] S. Feldman,et al. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double‐blind placebo‐controlled trial , 2005, The British journal of dermatology.
[5] P. Sfikakis. Behçet’s disease: a new target for anti-tumour necrosis factor treatment , 2002, Annals of the rheumatic diseases.
[6] D. Gladman,et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. , 2009, Arthritis and rheumatism.
[7] P. Theodossiadis,et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease , 2001, The Lancet.
[8] M. Mochizuki,et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. , 2004, The Journal of rheumatology.
[9] J. Braun,et al. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. , 2005, Arthritis and rheumatism.
[10] E. Keystone,et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. , 2004, Arthritis and rheumatism.
[11] A. Gottlieb,et al. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases , 2009, The Journal of dermatological treatment.
[12] A. Reiff,et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. , 2005, The Journal of rheumatology.
[13] C. Wouters,et al. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[14] P. Sfikakis,et al. Infliximab for chronic cystoid macular edema associated with uveitis. , 2004, American journal of ophthalmology.
[15] M. Dougados,et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. , 2006, Arthritis and rheumatism.
[16] T. Horiuchi,et al. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor-alpha. , 2004, Gastroenterology.
[17] A. Gottlieb,et al. Etanercept treatment for children and adolescents with plaque psoriasis. , 2008, The New England journal of medicine.
[18] M. Dougados,et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. , 2003, Arthritis and rheumatism.
[19] J. Avorn,et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[20] A. Zinsmeister,et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.
[21] Richard W. Martin,et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. , 2002, Arthritis and rheumatism.
[22] D. M. van der Heijde,et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. , 2004, Arthritis and rheumatism.
[23] T. Kvien,et al. A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases. , 2005, Clinical and experimental rheumatology.
[24] U. Kajermo,et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor‐α in the normal palmar eccrine sweat duct? , 2005, The British journal of dermatology.
[25] H. Erdem,et al. Evaluation of the short-term efficacy of NSAIDs on patients with active ankylosing spondylitis in daily practice: a 3-month, longitudinal, observational study , 2010, Rheumatology International.
[26] M. Dougados,et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed , 2004, Annals of the rheumatic diseases.
[27] A. Prieur,et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. , 2003, Arthritis and rheumatism.
[28] D. Gladman. Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis , 2008, Nature Clinical Practice Rheumatology.
[29] A. Reiff,et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. , 2000, The New England journal of medicine.
[30] Steven R Feldman,et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. , 2008, Journal of the American Academy of Dermatology.
[31] Y. Goekoop-Ruiterman,et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[32] A. Silman,et al. Predictors of Response to Anti-tnf-therapy among Patients with Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register , 2022 .
[33] R. Wallis. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. , 2008, The Lancet. Infectious diseases.
[34] D. Gjertson,et al. TNFα blockade in human diseases : An overview of efficacy and safety , 2008 .
[35] G. Lichtenstein. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial , 2008 .
[36] N. Katsilambros,et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. , 2004, Annals of internal medicine.
[37] C. Ritchlin. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor-alpha. , 2002, Current rheumatology reports.
[38] B. Feagan,et al. Clinically Meaningful Improvement in Health-Related Quality of Life in a Randomized Controlled Trial of Certolizumab Pegol Maintenance Therapy for Crohn's Disease , 2009, The American Journal of Gastroenterology.
[39] D. Symmons,et al. Guideline for anti-TNF-α therapy in psoriatic arthritis , 2005 .
[40] P. Tak,et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.
[41] C. Barnabe,et al. Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. , 2009, Seminars in arthritis and rheumatism.
[42] R. Baughman,et al. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. , 2008, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[43] C. Gabay,et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis , 2005, Annals of the rheumatic diseases.
[44] J. Niinimäki,et al. The Treatment of Disc Herniation-Induced Sciatica With Infliximab: One-Year Follow-up Results of FIRST II, a Randomized Controlled Trial , 2006, Spine.
[45] S. Schreiber,et al. Maintenance therapy with certolizumab pegol for Crohn's disease. , 2007, The New England journal of medicine.
[46] C. Roussos,et al. Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy , 2008, Annals of the rheumatic diseases.
[47] R. Tibshirani,et al. Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis , 2009, Arthritis research & therapy.
[48] N. Katsilambros,et al. Successful treatment of refractory adult-onset Still’s disease with infliximab. A prospective, non-comparative series of four patients , 2004, Clinical Rheumatology.
[49] A. Forbes,et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial , 2005, Gut.
[50] D. M. van der Heijde,et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial , 2008, Annals of the rheumatic diseases.
[51] R. D. du Bois,et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. , 2006, American journal of respiratory and critical care medicine.
[52] B. Dijkmans,et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases , 2009, Annals of the rheumatic diseases.
[53] X. Mariette,et al. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. , 2005, Annals of the rheumatic diseases.
[54] T. Arora,et al. Differences in binding and effector functions between classes of TNF antagonists. , 2009, Cytokine.
[55] M. Bala,et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. , 2005, Gastroenterology.
[56] W. Dixon,et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register , 2008, Annals of the rheumatic diseases.
[57] John Han,et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. , 2006, Arthritis and rheumatism.
[58] L. Dušek,et al. Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy , 2009, Annals of the rheumatic diseases.
[59] A. Kavanaugh,et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial , 2005, Annals of the rheumatic diseases.
[60] K. Lohr,et al. Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis , 2008, Annals of Internal Medicine.
[61] P. Rutgeerts,et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. , 1999, The New England journal of medicine.
[62] Matthias Schneider,et al. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. , 2007, The Journal of rheumatology.
[63] A. Moss,et al. Infliximab for induction and maintenance therapy for ulcerative colitis. , 2006, Gastroenterology.
[64] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[65] P. Dieudé,et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. , 2009, Joint, bone, spine : revue du rhumatisme.
[66] Xiao-Yu Song,et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.
[67] I. Olivieri,et al. Single-center series and systematic review of randomized controlled trials of malignancies in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis receiving anti-tumor necrosis factor alpha therapy: is there a need for more comprehensive screening procedures? , 2009, Arthritis and rheumatism.
[68] M. Bandt,et al. Vasculitides induced by TNFα antagonists: a study in 39 patients in France , 2006 .
[69] R S Wallis,et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[70] R. Schneider,et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. , 2003, Arthritis and rheumatism.
[71] M. Khamashta,et al. Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases , 2007, Medicine.
[72] Mahboob Rahman,et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study , 2008, Annals of the rheumatic diseases.
[73] K. Minden,et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. , 2008, The New England journal of medicine.
[74] D. Gjertson,et al. TNFα blockade in human diseases: Mechanisms and future directions , 2008 .
[75] John L. Johnson,et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis , 2004, AIDS.
[76] Mahboob Rahman,et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. , 2006, Arthritis and rheumatism.
[77] W. Koldingsnes,et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. , 2008, Arthritis and rheumatism.
[78] W Domschke,et al. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. , 2001, Gastroenterology.
[79] Matthias Schneider,et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. , 2006, Arthritis and rheumatism.
[80] D. Symmons,et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. , 2005, Rheumatology.
[81] P. Blackshear,et al. Transmembrane TNF protects mutant mice against intracellular bacterial infections, chronic inflammation and autoimmunity , 2006, European journal of immunology.
[82] G. Baron,et al. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS). , 2004, Arthritis and rheumatism.
[83] J. Saurat,et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus , 2006, Journal of the European Academy of Dermatology and Venereology : JEADV.
[84] H. Zeidler,et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. , 2005, Rheumatology.
[85] Stanley B. Cohen,et al. Etanercept Treatment for Autoimmune Inner Ear Disease: Results of a Pilot Placebo-Controlled Study , 2005, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.
[86] Mahboob Rahman,et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial , 2009, The Lancet.
[87] C. Edwards,et al. Anti-TNF-induced lupus. , 2009, Rheumatology.
[88] J. Reveille,et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease , 2007, Annals of the rheumatic diseases.
[89] R. Wallis,et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. , 2006, The Journal of infectious diseases.
[90] D. Hommes,et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. , 2003, Gastroenterology.
[91] Mahboob Rahman,et al. Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis , 2007, Annals of Internal Medicine.
[92] E. Sasso,et al. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. , 2009, Clinical immunology.
[93] P. Rutgeerts,et al. Caspase activation and apoptosis induction by adalimumab: Demonstration in vitro and in vivo in a chimeric mouse model , 2006, Inflammatory bowel diseases.
[94] Steven P. Cohen,et al. Randomized, Double-blind, Placebo-controlled, Dose-response, and Preclinical Safety Study of Transforaminal Epidural Etanercept for the Treatment of Sciatica , 2009, Anesthesiology.
[95] A. Katsambas,et al. Infliximab in dermatological treatment: beyond psoriasis , 2008, Expert opinion on biological therapy.
[96] J. Sharp,et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. , 2004, Arthritis and rheumatism.
[97] Mahboob Rahman,et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. , 2008, Arthritis and rheumatism.
[98] B. Dijkmans,et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis , 2008, Annals of the rheumatic diseases.
[99] A. Forbes,et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial , 2003, Gut.
[100] P. Sfikakis,et al. TUMOR NECROSIS FACTOR ANTAGONISTS: Preliminary Evidence for an Emerging Approach in the Treatment of Ocular Inflammation , 2007, Retina.
[101] L. Klareskog,et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense , 2003, Annals of the rheumatic diseases.
[102] M. de Bandt,et al. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. , 2006, Joint, bone, spine : revue du rhumatisme.
[103] S. Targan,et al. Safety and Efficacy of Adalimumab (D2E7) in Crohn's Disease Patients with an Attenuated Response to Infliximab , 2005, The American Journal of Gastroenterology.
[104] S. Hayat. Infliximab plus Prednisone or Placebo plus Prednisone for the Initial Treatment of Polymyalgia Rheumatica: A Randomized Trial , 2008 .
[105] P. Sfikakis,et al. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. , 2005, Diabetes care.
[106] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[107] S. Rantapää-Dahlqvist,et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα , 2004, Annals of the rheumatic diseases.
[108] K. Minden,et al. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis. , 2009, Rheumatology.
[109] G. Kollias,et al. Tumor necrosis factor biology in experimental and clinical arthritis , 2003, Current opinion in rheumatology.
[110] V. Strand,et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Arthritis and rheumatism.
[111] F. Nestle,et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.
[112] J. Avorn,et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. , 2006, Arthritis and rheumatism.
[113] M. Aringer,et al. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. , 2004, Arthritis and rheumatism.
[114] H. Zeidler,et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. , 2003, Arthritis and rheumatism.
[115] J. Gómez-Reino,et al. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. , 2007, Arthritis and rheumatism.
[116] L. Kagen,et al. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients , 2006, Annals of the rheumatic diseases.
[117] M. Inanç,et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. , 2005, Arthritis and rheumatism.
[118] George Kollias,et al. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. , 2002, Cytokine & growth factor reviews.
[119] X. Mariette,et al. Tumour necrosis factor α blocking agents in refractory adult Still’s disease: an observational study of 20 cases , 2004 .
[120] Matthias Schneider,et al. Infections in patients with rheumatoid arthritis treated with biologic agents. , 2005, Arthritis and rheumatism.
[121] P. Woo,et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. , 2008, Rheumatology.
[122] C. Turesson,et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. , 2005, The Journal of rheumatology.
[123] H. Zeidler,et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial , 2002, The Lancet.
[124] E. Chung,et al. Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-&agr;, in Patients With Moderate-to-Severe Heart Failure: Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial , 2003, Circulation.
[125] F. Barkhof,et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2 , 1996, Neurology.
[126] D. Paty,et al. TNF neutralization in MS , 1999, Neurology.
[127] A. Till,et al. Current State of Biologicals in the Management of Systemic Vasculitis , 2007, Annals of the New York Academy of Sciences.
[128] I. Foeldvari,et al. The German etanercept registry for treatment of juvenile idiopathic arthritis , 2004, Annals of the rheumatic diseases.
[129] L. Klareskog,et al. Adalimumab (Humira®) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade®) or etanercept (Enbrel®): results from the STURE registry at Karolinska University Hospital , 2005 .
[130] K. Siamopoulos,et al. Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[131] P. Sfikakis,et al. Regression of neovascular age-related macular degeneration following infliximab therapy. , 2005, American journal of ophthalmology.
[132] P. Sfikakis,et al. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-related macular degeneration. , 2009, American journal of ophthalmology.
[133] E. Keystone. Safety of biologic therapies--an update. , 2005, The Journal of rheumatology. Supplement.
[134] N. Kavantzas,et al. Intravitreal administration of the anti-TNF monoclonal antibody Infliximab in the rabbit , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.
[135] Y. Ozyazgan,et al. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study. , 2005, The Journal of rheumatology.
[136] D. Gladman,et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. , 2007, Arthritis and rheumatism.
[137] H. Zeidler,et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis , 2004, Annals of the rheumatic diseases.
[138] F. Breedveld,et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. , 2006, Arthritis and rheumatism.
[139] Å. Danielsson,et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.
[140] B. Dijkmans,et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). , 2005, Arthritis and rheumatism.
[141] D. Furst,et al. Etanercept Therapy in Rheumatoid Arthritis , 1999, Annals of Internal Medicine.
[142] L. Cavazzini,et al. Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review. , 2010, Seminars in arthritis and rheumatism.
[143] P. Sfikakis,et al. Infliximab treatment-induced formation of autoantibodies is common in Behçet's disease. , 2007, Clinical and experimental rheumatology.
[144] J. McMurray,et al. Targeted Anticytokine Therapy in Patients With Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL) , 2004, Circulation.
[145] B. Sands,et al. A double-blinded, randomized, placebo-controlled trial of infliximab in subjects with active pulmonary sarcoidosis. , 2006, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.
[146] S. van der Linden,et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis , 2004, Annals of the rheumatic diseases.
[147] J. Braun,et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. , 2003, Arthritis and rheumatism.
[148] C. Denton,et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis , 2008, Annals of the rheumatic diseases.
[149] A. Nesbitt,et al. In Vitro Complement-Dependent Cytotoxicity and Antibody-Dependent Cellular Cytotoxicity by the Anti-TNF Agents Adalimumab, Etanercept, Infliximab, and Certolizumab Pegol (CDP870): 807 , 2005 .
[150] D. Schroeder,et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. , 2003, Chest.
[151] S. Ohno,et al. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations. , 2007, Rheumatology.
[152] M. Broder,et al. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. , 2006, Seminars in arthritis and rheumatism.
[153] B. Miller,et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. , 2006, Journal of the American Academy of Dermatology.
[154] A. Gottlieb,et al. Treatment recommendations for psoriatic arthritis , 2008, Annals of the rheumatic diseases.
[155] P. Angus,et al. Hepatitis B and C virus infections and anti‐tumor necrosis factor‐α therapy: Guidelines for clinical approach , 2006, Journal of gastroenterology and hepatology.
[156] A. Silman,et al. Anti-tumor necrosis factor alpha therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer. , 2004, Arthritis and rheumatism.
[157] N. Goel,et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study , 2008, Annals of the rheumatic diseases.
[158] John C. Davis,et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. , 2008, Arthritis and rheumatism.
[159] L. Dušek,et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. , 2007, Clinical and experimental rheumatology.
[160] P. Mease,et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial , 2000, The Lancet.
[161] L. Klareskog,et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial , 2004, The Lancet.
[162] D Emilie,et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. , 2009, Arthritis and rheumatism.
[163] D. Gladman,et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.
[164] J. Belaiche,et al. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease , 2002, American Journal of Gastroenterology.
[165] J. Kremer,et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.
[166] C. Kittas,et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. , 2005, Arthritis and rheumatism.
[167] K. Psathakis,et al. Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[168] P. Sfikakis,et al. Psoriasis occurring during anti-TNF-α therapy: causal effect or unrelated? , 2006 .
[169] T. Horiuchi,et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. , 2005, Gastroenterology.
[170] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[171] M. Crow,et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies , 2008, Annals of the rheumatic diseases.
[172] H. H. Kuper,et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice , 2007, Annals of the rheumatic diseases.
[173] S. Schreiber,et al. Certolizumab pegol for the treatment of Crohn's disease. , 2007, The New England journal of medicine.
[174] A. Silman,et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. , 2006, Arthritis and rheumatism.
[175] A. Volpe,et al. Anti-TNFalpha blockers, autoantibodies and autoimmune diseases. , 2009, Joint, bone, spine : revue du rhumatisme.